Botulinum Toxin Market: Drivers
Increasing number of procedures
with botulinum toxin along with increasing approved indication is expected to
drive growth of the global Botulinum
Toxin Market. Frequent approvals of novel botulinum toxin products for
different indications are expected to drive growth of the Botulinum toxin
market in near future. For instance, in 2016, Ipsen S.A. received the U.S. Food
and Drug Administration (FDA) approval for its Dysport (abobotulinumtoxinA)
injection indicated for the treatment of pediatric lower limb (PLL) spasticity
in children of age two years and older. In 2017, company received the FDA
approval for same product to use in adults. In 2017, Allergan plc. received FDA
approval for BOTOX Cosmetic (OnabotulinumtoxinA) for new indication in forehead
lines, and previously the product has been approved for the treatment of ,
crow's feet lines, and glabellar lines. With this approval company has expanded
the indication of its product in the temporary improvement in the appearance of
moderate to severe forehead lines associated with frontalis muscle activity in
adults. In 2014, Allergan Inc. received approval for its BOTOX (Botulinum toxin
type A) from Medicines and Healthcare Products Regulatory Agency (MHRA) in U.K.
BOTOX was approved in the U.K. for treatment of ankle disability due to lower
limb spasticity associated with stroke in adults. In 2016, Daewoong Pharmaceutical
Co., Ltd received approval for its botulinum toxin Nabota in Mexico and India.
Nabota was introduced by Daewoong Pharmaceutical Co., Ltd in South Korea in
2014. In 2015, Merz North America, the U.S. subsidiary of the global Merz
Pharma Group, received U.S. FDA approval for Xeomin (incobotulinumtoxinA)
indicated for the treatment of upper limb spasticity (ULS) in adult patients.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1518
Furthermore, increasing trend of
botulinum toxin in cosmetic procedures is also expected to increase the growth
of botulinum toxin market in near future. For instance, according to a report
published by American Society of Plastic Surgeons in 2016, around 7,056,255
cosmetic minimally-invasive procedures were performed with Botulinum toxin Type
A (Botox, Dysport, and Xeomin), there was an increase of 4% in procedures as
compared to 2015.
Botulinum toxin is a product
produced by naturally occurring Clostridium botulinum bacteria. This bacteria
is found in soil and marine sediments and can produce harmful neurotoxin
botulinum toxin. Botulinum toxin is a ‘blocking agent’ which inhibits the
release of certain neurotransmitters, specifically acetylcholine, from the
endings of the motor nerves. There are about eight types of botulinum toxin
named from type A to H. Botulinum toxin type A and botulinum toxin type B are
majorly used in cosmetic procedures for the treatment of various facial
conditions, its commercially marketed under the brand name Botox. Botulinum
toxin type A and B are also used in medical applications for treatment of various
diseases such as dystonia, chronic migraines, and spasticity.
Botulinum Toxin Market: Regional
analysis
North America is expected to hold
a dominant position in the global botulinum toxin market, owing to increasing
trend of cosmetic procedures in the region. For instance, according to a report
published by American Society of Plastic Surgeons in 2016, around US$ 16.4
billion was spent on cosmetic procedures in the U.S. and in 2017, around 7.2
million botulinum injections were used in the U.S. for cosmetic procedures.
Increasing number of cosmetic procedures in the key region of North America is
expected to drive the growth of the botulinum toxin market in near future.
Furthermore, Asia Pacific is expected to show rapid growth in botulinum toxin
market, owing to increasing R&D and approval of novel products in China.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/botulinum-toxin-market-1518
For instance, in January 2018,
Daewoong Pharmaceutical Co. Ltd., a Korean company, received approval from the
Chinese authorities to conduct clinical trials for botulinum toxin Nabota in
China.
Botulinum Toxin Market: Key
Players
Key players operating in global
botulinum toxin market includes Ipsen group, Allergan Plc., Medytox Inc., Merz
GmbH and Co. KGaA, US Worldmed, LLC, Lanzhou Institute of Biological Products
Co. Ltd., Revance Therapeutics, Inc., and Daewoong Pharmaceutical Co., Ltd.
Major players in market are involved in strategic collaborations to develop new
products. For instance, in February 2018, Mylan N.V. and Revance Therapeutics,
Inc. underwent strategic collaboration and license agreement for the
development and commercialization of a proposed biosimilar to BOTOX
(onabotulinumtoxinA). Furthermore, key players are focusing on receiving
approvals of its product in key market to expand their presence in global
market. For instance, in February 2018, Medytox Inc. filed a new drug
application with the China Food and Drug Administration (CFDA) to its botulinum
neurotoxin product Meditoxin in China.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1518
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment